PROGNOSTIC SIGNIFICANCE OF IMMUNOHISTOCHEMICAL EXPRESSION OF MGMT IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH TEMAZOLAMIDE

被引：0
|
作者：
Balasubramaniam, Anandh
Santosh, Vani
Arivazhagan, A.
Balaram, T.
Chandramouli, B. A.
Hegde, A. S.
Somasundaram, Kumaravel
Kondaiah, P.
Rao, M. R. S.
机构：
来源：
NEURO-ONCOLOGY | 2009年 / 11卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：646 / 646
页数：1
相关论文
共 50 条
  • [1] MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Gerstner, E. R.
    Yip, S.
    Wang, D. L.
    Louis, D. N.
    Iafrate, A. J.
    Batchelor, T. T.
    NEUROLOGY, 2009, 73 (18) : 1509 - 1510
  • [2] PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION STATUS IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH BCNU WAFER IMPLANTATION: A PROSPECTIVE PATIENT COHORT
    Philippe, Metellus
    Isabelle, Nanni-Metellus
    Olivier, Chinot
    Frederic, Fina
    Stephane, Fuentes
    Henry, Dufour
    Marylin, Barrie
    L'Houcine, Ouafik
    Dominique, Figarella-Branger
    NEURO-ONCOLOGY, 2011, 13 : 56 - 56
  • [3] The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
    Villani, Veronica
    Casini, Beatrice
    Pace, Andrea
    Prosperini, Luca
    Carapella, Carmine M.
    Vidiri, Antonello
    Fabi, Alessandra
    Carosi, Andmariantonia
    DISEASE MARKERS, 2015, 2015
  • [4] PROGNOSTIC AND PREDICTIVE SIGNIFICANCE Of MGMT PROMOTER METHYLATION AND PROTEIN EXPRESSION IN GLIOBLASTOMA PATIENTS
    Spiegl-Kreinecker, S.
    Pirker, C.
    Filipits, M.
    Loetsch, D.
    Buchroithner, J.
    Pichler, J.
    Silye, R.
    Micksche, M.
    Fischer, J.
    Berger, W.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1080 - 1080
  • [5] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Consolación Melguizo
    Jose Prados
    Beatriz González
    Raul Ortiz
    Angel Concha
    Pablo Juan Alvarez
    Roberto Madeddu
    Gloria Perazzoli
    Jaime Antonio Oliver
    Rodrigo López
    Fernando Rodríguez-Serrano
    Antonia Aránega
    Journal of Translational Medicine, 10
  • [6] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Melguizo, Consolacion
    Prados, Jose
    Gonzalez, Beatriz
    Ortiz, Raul
    Concha, Angel
    Juan Alvarez, Pablo
    Madeddu, Roberto
    Perazzoli, Gloria
    Antonio Oliver, Jaime
    Lopez, Rodrigo
    Rodriguez-Serrano, Fernando
    Aranega, Antonia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [7] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Gonzalez-Astorga, B.
    Luque, R.
    Castellon, V.
    Gonzalez, E.
    Sanchez, C.
    Soberino, J.
    Gonzalez, C.
    Ruiz, J.
    Zurita, M.
    Delgado, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S794 - S794
  • [8] Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma
    Weller, Michael
    Oppong, Felix Boakye
    Vanlancker, Maureen
    Stupp, Roger
    Nabors, Louis B.
    Chinot, Olivier L.
    Wick, Wolfgang
    Preusser, Matthias
    Gorlia, Thierry
    Le Rhun, Emilie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma
    Le Rhun, Emilie
    Oppong, Felix Boakye
    Vanlancker, Maureen
    Stupp, Roger
    Nabors, Burt
    Chinot, Olivier
    Wick, Wolfgang
    Preusser, Matthias
    Gorlia, Thierry
    Weller, Michael
    NEURO-ONCOLOGY, 2022, 24 (09) : 1533 - 1545
  • [10] The clinical significance of fascin expression in a newly diagnosed primary glioblastoma
    Park, Ki-Su
    Lee, Hye Won
    Park, Seong-Hyun
    Park, Tae In
    Hwang, Jeong-Hyun
    JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (03) : 495 - 503
12345